Advantages of Q-Sera’s Technology

Current technologies in the blood collection tube market have been around for many years, with the mainstay being a simple silica-based serum tube. Although thrombin-based serum tubes are available to clot samples faster, these tubes are not effective against higher concentrations of heparin and other anticoagulants and are more expensive. Plasma samples can be produced by removing cells without clotting, however the resultant plasma contains all the clotting factors and remnant cells and is not optimal for biochemical analysis.

UNMET NEED: A serum tube which clots rapidly and produces High Quality Serum, has minimal issues with poorly clotted samples, ideally is effective against anticoagulated samples and is low cost.

Current Technologies

Serum: Silica Based Clotting Activator Tube

  • Leader in the market
  • Normal blood 15-30 min to clot
  • Partial or re-clotting can lead to inaccurate analyte readings or can affect equipment
  • Anticoagulated blood takes longer to clot (if at all).

Serum: Thrombin ‘Rapid serum’ Tube

  • Fast clotting
  • Not effective at higher heparin levels
  • High cost per tube

Plasma Tube

  • Plasma sample not optimal for biochemistry analysis
  • Poor sample stability

Market pressures

Anticoagulant Use Increasing

  • Increase in cardiac and dialysis use in hospitals
  • Increasing use of FXa inhibitors and direct thrombin inhibitors in the community setting

Rapid and Accurate Results

  • Increased focus on achieving turn-around time (TAT) - time from receipt of sample to analyte results
  • Increasing need for 'STAT' or Urgent tubes - fast and accurate diagnosis (e.g.) Troponin biomarker for myocardial infarction.

Enhanced Laboratory Efficiency

  • Efficient batch processing
  • Justification of cost / benefit
  • Reduction in laboratory errors and re-sampling
  • 7 day sample storage


Fast and complete clotting
  • Clots anticoagulated blood
  • Majority of samples < 5min to clot
  • Fast and accurate testing
High quality serum
  • Minimal re-clotting in serum
  • Minimal cellular activity in serum
  • Stability of key analytes over 7 days
Enhanced laboratory efficiency
  • Efficiency in batch processing - reduces turn around time
  • Minimises equipment downtime
  • Accurate diagnosis and improved patient care
Commercial utility and advantage
  • Can be developed in standard plastic tubes
  • Potential 18m shelf life at room temperature / irradiation stability
  • Low cost active enabling mass market entry
  • Patent protection through 2034